Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

[1]  P. Sorger,et al.  Temporal and spatial topography of cell proliferation in cancer , 2021, bioRxiv.

[2]  C. Yau,et al.  The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers , 2021, Clinical Cancer Research.

[3]  R. Weinberg,et al.  Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. , 2020, Cancer discovery.

[4]  Julia Casado,et al.  Agile workflow for interactive analysis of mass cytometry data , 2020, bioRxiv.

[5]  B. Rueda,et al.  Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer , 2020, Cancers.

[6]  P. Park,et al.  Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer , 2020, Nature Communications.

[7]  P. Park,et al.  Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer , 2020, Nature Communications.

[8]  R. Bourgon,et al.  Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer , 2019, Nature Communications.

[9]  B. Clarke,et al.  High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation , 2019, Journal of Immunotherapy for Cancer.

[10]  D. Matei,et al.  Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer , 2019, npj Precision Oncology.

[11]  Zu-hua Gao,et al.  High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints , 2019, International journal of molecular sciences.

[12]  J. Roa,et al.  Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. , 2018, Gynecologic oncology.

[13]  Wyeth W. Wasserman,et al.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.

[14]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[15]  Sandro Santagata,et al.  Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.

[16]  K. Pienta,et al.  Targeting the tumour stroma to improve cancer therapy , 2018, Nature Reviews Clinical Oncology.

[17]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[18]  L. Steinmetz,et al.  Human haematopoietic stem cell lineage commitment is a continuous process , 2017, Nature Cell Biology.

[19]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[20]  Yang Bai,et al.  The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer , 2017, Oncotarget.

[21]  M. Xia,et al.  The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients , 2016, Oncotarget.

[22]  R. Kuick,et al.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.

[23]  Lauren L. Ritterhouse,et al.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.

[24]  H. Feilotter,et al.  BRCA1 Haploinsufficiency Leads to Altered Expression of Genes Involved in Cellular Proliferation and Development , 2014, PloS one.

[25]  Marcus Schmidt,et al.  Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study. , 2014, Oncology reports.

[26]  I. Christensen,et al.  Prognostic value of tissue protein expression levels of MIB‐1 (Ki‐67) in Danish ovarian cancer patients. From the ‘MALOVA’ ovarian cancer study , 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  M. Quinn,et al.  Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. , 2010, Current cancer drug targets.

[29]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.

[30]  S. Furuta,et al.  Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Levine,et al.  Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. , 2002, Gynecologic oncology.

[32]  Robert C. Wolpert,et al.  A Review of the , 1985 .